Cited by 432Metal complexes synthesis and propertiesCell death mechanisms and regulationCancer therapeutics and mechanisms

The DOI matches its Crossref record.

Cisplatin Biochemical Mechanism of Action: From Cytotoxicity to Induction of Cell Death Through Interconnections Between Apoptotic and Necrotic Pathways

Fuertes, M., Castilla, J., Alonso, C., Pérez, J.·2003·Current Medicinal Chemistry

DOI 10.2174/0929867033368484

Open this paper in CoChat — free account

Abstract

Although cisplatin, cis-diamminedichloroplatinum(II), has been successfully used in the chemotherapy of cancer for more than 25 years, its biochemical mechanism of action is still unclear. The current accepted paradigm about cisplatin mechanism of action is that the drug induces its cytotoxic properties through binding to nuclear DNA and subsequent interference with normal transcription, and/or DNA replication mechanisms. If cisplatin-DNA adducts are not efficiently processed by cell machinery, cytotoxic processes eventually end up in cell death. However, before cisplatin enters the cell it may bind to phospholipids and phosphatidylserine in the cell membrane. In addition, in the cytoplasm many potential platinum-binding sites are also available, including RNA and sulfur-containing biomolecules. Moreover, there is much evidence suggesting that the cytotoxic effects induced by binding of cisplatin to non-DNA targets (especially proteins) may contribute to its biochemical mechanism of action. On the other hand, it has been found that several factors such as the dose of drug as well as the metabolic condition of the cell subjected to cisplatin aggression, may determine that cancer cells die through apoptosis or necrosis. In fact, it has recently been reported that both mechanisms of cell demise work in concert so that within a population of tumour cells there is a continuum of possible modes of cell death.

Integrity signals

Registry

Crossref · 10.2174/0929867033368484

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Still being checked.

Sorted by citations

Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E., & Adjei, A. A. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.5.584 · Cited by 3,991
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
Fuertes, M. A., Alonso‐Moreno, C., & Pérez, J. M. (2003) · Chemical Reviews · doi:10.1021/cr020010d · Cited by 896
Self-citation
The role of p53 in cancer drug resistance and targeted chemotherapy
Hientz, K., Mohr, A., Bhakta-Guha, D., & Efferth, T. (2016) · Oncotarget · doi:10.18632/oncotarget.13475 · Cited by 612
Approaching tumour therapy beyond platinum drugs
Bergamo, A., Gaiddon, C., Schellens, J. H. M., Beijnen, J. H., & Sava, G. (2011) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2011.09.030 · Cited by 515
Anticancer peptide: Physicochemical property, functional aspect and trend in clinical application (Review)
Chiangjong, W., Chutipongtanate, S., & Hongeng, S. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5099 · Cited by 402
Modifications of DNA by platinum complexes
Brabec, V., & Kašpárková, J. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.04.006 · Cited by 374
What do we know about the reduction of Pt(IV) pro-drugs?
Wexselblatt, E., & Gibson, D. (2012) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2012.06.013 · Cited by 372
Cisplatin and Aminoglycoside Antibiotics: Hearing Loss and Its Prevention
Schacht, J., Talaska, A. E., & Rybak, L. P. (2012) · The Anatomical Record · doi:10.1002/ar.22578 · Cited by 348
Platinum Anticancer Coordination Compounds: Study of DNA Binding Inspires New Drug Design
Reedijk, J. (2009) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.200900054 · Cited by 343
Anticancer cyclometalated complexes of platinum group metals and gold
Cutillas, N., Yellol, G. S., Haro, C. D., Vicente, C., Rodrı́guez, V., & Ruiz, J. (2013) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2013.03.024 · Cited by 332
Chemotherapy Resistance in Advanced Ovarian Cancer Patients
Pokhriyal, R., Hariprasad, R., Kumar, L., & Hariprasad, G. (2019) · Biomarkers in Cancer · doi:10.1177/1179299x19860815 · Cited by 282
Ru(II) dyads derived from α-oligothiophenes: A new class of potent and versatile photosensitizers for PDT
Shi, G., Monro, S. M. A., Hennigar, R. A., Colpitts, J., Fong, J., Kasimova, K., Yin, H., DeCoste, R. C., Spencer, C., Chamberlain, L., et al. (2014) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2014.04.012 · Cited by 284
Anti-inflammatory activity of nanocrystalline silver in a porcine contact dermatitis model
Nadworny, P. L., Wang, J., Tredget, E. E., & Burrell, R. E. (2008) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2008.04.006 · Cited by 272
Cisplatin Preferentially Binds Mitochondrial DNA and Voltage-Dependent Anion Channel Protein in the Mitochondrial Membrane of Head and Neck Squamous Cell Carcinoma: Possible Role in Apoptosis
Yang, Z., Schumaker, L. M., Egorin, M. J., Zuhowski, E. G., Guo, Z., & Cullen, K. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1037 · Cited by 270
Pentamidine reverses the splicing defects associated with myotonic dystrophy
Warf, M. B., Nakamori, M., Matthys, C. M., Thornton, C. A., & Berglund, J. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903234106 · Cited by 265
Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology
Sutendra, G., & Michelakis, E. D. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00038 · Cited by 275
Biophysics in cancer: The relevance of drug-membrane interaction studies
Alves, A. C., Ribeiro, D., Nunes, C., & Reis, S. (2016) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2016.06.025 · Cited by 245
Protection against Cisplatin-Induced Toxicities by N-Acetylcysteine and Sodium Thiosulfate as Assessed at the Molecular, Cellular, and in Vivo Levels
Dickey, D. T., Wu, Y. J., Muldoon, L. L., & Neuwelt, E. A. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.087601 · Cited by 225
Platinum–DNA Interactions and Subsequent Cellular Processes Controlling Sensitivity to Anticancer Platinum Complexes
Ahmad, S. (2010) · Chemistry & Biodiversity · doi:10.1002/cbdv.200800340 · Cited by 222
Regulation of PUMA-α by p53 in cisplatin-induced renal cell apoptosis
Jiang, M., Wei, Q., Wang, J., Du, Q., Yu, J., Zhang, L., & Dong, Z. (2006) · Oncogene · doi:10.1038/sj.onc.1209440 · Cited by 214
Caspase-1–deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis
Faubel, S. G., Ljubanović, D. G., Reznikov, L. L., Somerset, H., Dinarello, C. A., & Edelstein, C. L. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.66010.x · Cited by 196
Mitochondria as a critical target of the chemotheraputic agent cisplatin in head and neck cancer
Cullen, K. J., Yang, Z., Schumaker, L. M., & Guo, Z. (2007) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-006-9059-5 · Cited by 197
Suppression of Rev3, the catalytic subunit of Polζ, sensitizes drug-resistant lung tumors to chemotherapy
Doles, J., Oliver, T. G., Cameron, E. R., Hsu, G., Jacks, T., Walker, G. C., & Hemann, M. T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1011409107 · Cited by 190
Pt( iv ) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action
Raveendran, R., Braude, J. P., Wexselblatt, E., Novohradský, V., Stuchlíková, O., Brabec, V., Gandin, V., & Gibson, D. (2016) · Chemical Science · doi:10.1039/c5sc04205d · Cited by 183
The mechanism of action of platinum anticancer agents—what do we really know about it?
Gibson, D. (2009) · Dalton Transactions · doi:10.1039/b918871c · Cited by 181
Role of p53 in cisplatin-induced tubular cell apoptosis: dependence on p53 transcriptional activity
Jiang, M., Yi, X., Hsu, S., Wang, C., & Dong, Z. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00262.2004 · Cited by 176
Cisplatin for cancer therapy and overcoming chemoresistance
Ranasinghe, R., Mathai, M. L., & Zulli, A. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e10608 · Cited by 169
Docking Studies on DNA Intercalators
Gilad, Y., & Senderowitz, H. (2013) · Journal of Chemical Information and Modeling · doi:10.1021/ci400352t · Cited by 153
Role of the Glutathione Metabolic Pathway in Lung Cancer Treatment and Prognosis: A Review
Yang, P., Ebbert, J. O., Sun, Z., & Weinshilboum, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.7110 · Cited by 151
Effects of hydroxyl radical scavenging on cisplatin-induced p53 activation, tubular cell apoptosis and nephrotoxicity
Jiang, M., Wei, Q., Pabla, N., Dong, G., Wang, C., Yang, T., Smith, S. B., & Dong, Z. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.01.010 · Cited by 149
Perspectives in bioinorganic chemistry of some metal based therapeutic agents
Ahmad, S., Isab, A. A., Ali, S., & Al‐Arfaj, A. R. (2005) · Polyhedron · doi:10.1016/j.poly.2005.11.004 · Cited by 147
Long-term outcome associated with intratumoral chemotherapy with cisplatin for cutaneous tumors in equidae: 573 cases (1995–2004)
Théon, A. P., Wilson, W. D., Magdesian, K. G., Pusterla, N., Snyder, J. R., & Galuppo, L. D. (2007) · Journal of the American Veterinary Medical Association · doi:10.2460/javma.230.10.1506 · Cited by 132
Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model
Dickey, D. T., Muldoon, L. L., Kraemer, D. F., & Neuwelt, E. A. (2004) · Hearing Research · doi:10.1016/j.heares.2004.02.007 · Cited by 130
Epidemiology of Lung Cancer Prognosis: Quantity and Quality of Life
Yang, P. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-416-2_24 · Cited by 122
Poly(ADP-Ribose) Polymerases: Homology, Structural Domains and Functions. Novel Therapeutical Applications
Nguewa, P., Fuertes, M. A., Valladares, B., Alonso‐Moreno, C., & Pérez, J. M. (2004) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2004.01.001 · Cited by 120
Self-citation
Anti-inflammatory activity of nanocrystalline silver-derived solutions in porcine contact dermatitis
Nadworny, P. L., Wang, J., Tredget, E. E., & Burrell, R. E. (2010) · Journal of Inflammation · doi:10.1186/1476-9255-7-13 · Cited by 120
Up-regulation of 14-3-3ζ in Lung Cancer and Its Implication as Prognostic and Therapeutic Target
Fan, T., Li, R., Todd, N. W., Qiu, Q., Fang, H.-B., Wang, H., Shen, J., Zhao, Y., Caraway, N. P., Katz, R. L., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0090 · Cited by 116
Bystander or No Bystander for Gene Directed Enzyme Prodrug Therapy
Dachs, G. U., Hunt, M. A., Syddall, S. P., Singleton, D. C., & Patterson, A. V. (2009) · Molecules · doi:10.3390/molecules14114517 · Cited by 110
Amifostine Protective Effect on Cisplatin‐Treated Rat Testis
Lirdi, L. C., Stumpp, T., Sasso‐Cerri, E., & Miraglia, S. M. (2008) · The Anatomical Record · doi:10.1002/ar.20693 · Cited by 113
Photosensitive Pt(IV)–azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced efficacy in vivo
Xiao, H., Noble, G. T., Stefanick, J. F., Qi, R., Kiziltepe, T., Jing, X., & Bilgiçer, B. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.10.020 · Cited by 104
MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer
Sun, N., Sun, X., Chen, B., Cheng, H., Feng, J., Cheng, L., & Lu, Z. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1046-1 · Cited by 100
RB signaling prevents replication-dependent DNA double-strand breaks following genotoxic insult
Bosco, E. E. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkg919 · Cited by 97
Targeted therapy vs. DNA-adduct formation-guided design: thoughts about the future of metal-based anticancer drugs
Sava, G., Jaouen, G., Hillard, E. A., & Bergamo, A. (2012) · Dalton Transactions · doi:10.1039/c2dt30075c · Cited by 98
A dual-targeting, apoptosis-inducing organometallic half-sandwich iridium anticancer complex
Novohradský, V., Zerzánková, L., Štěpánková, J., Kisova, A., Kostrhunová, H., Liu, Z., Sadler, P. J., Kašpárková, J., & Brabec, V. (2014) · Metallomics · doi:10.1039/c4mt00112e · Cited by 97
Advanced Ovarian Cancer: Multiparametric MR Imaging Demonstrates Response- and Metastasis-specific Effects
Sala, E., Kataoka, M., Priest, A. N., Gill, A. B., McLean, M. A., Joubert, I., Graves, M. J., Crawford, R., Jimenez‐Liñan, M., Earl, H. M., et al. (2012) · Radiology · doi:10.1148/radiol.11110175 · Cited by 96
RNA-Pt Adducts Following Cisplatin Treatment ofSaccharomyces cerevisiae
Hostetter, A. A., Osborn, M. F., & DeRose, V. J. (2011) · ACS Chemical Biology · doi:10.1021/cb200279p · Cited by 95
Involvement of cytochrome P450 in cisplatin treatment: implications for toxicity
Quintanilha, J. C. F., de Sousa, V. M., Visacri, M. B., Amaral, L. S., Santos, R. M. M., Zambrano, T., Salazar, L. A., & Moriel, P. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3358-x · Cited by 95
Activation of the DNA Damage Checkpoint in Yeast Lacking the Histone Chaperone Anti-Silencing Function 1
Ramey, C. J., Howar, S. R., Adkins, M. W., Linger, J. G., Spicer, J., & Tyler, J. K. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.23.10313-10327.2004 · Cited by 99
Berberine in combination with cisplatin suppresses breast cancer cell growth through induction of DNA breaks and caspase-3-dependent apoptosis
Zhao, Y., Jing, Z., Li, Y., & Mao, W. (2016) · Oncology Reports · doi:10.3892/or.2016.4785 · Cited by 92
New insights into the molecular and epigenetic effects of antitumor Pt(IV)-valproic acid conjugates in human ovarian cancer cells
Novohradský, V., Zerzánková, L., Štěpánková, J., Vrána, O., Raveendran, R., Gibson, D., Kašpárková, J., & Brabec, V. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.04.003 · Cited by 91
In vitro evaluation of biomarkers for cisplatin-induced nephrotoxicity using HK-2 human kidney epithelial cells
Sohn, S.-J., Kim, S. Y., Kim, H. S., Chun, Y., Han, S. Y., Kim, S. H., & Moon, A. (2012) · Toxicology Letters · doi:10.1016/j.toxlet.2012.12.015 · Cited by 89
Dichloroacetate shifts the metabolism from glycolysis to glucose oxidation and exhibits synergistic growth inhibition with cisplatin in HeLa cells
Fang, C. (2010) · International Journal of Oncology · doi:10.3892/ijo.2010.851 · Cited by 88
Molecular and Cellular Mechanisms of Cytotoxic Activity of Vanadium Compounds against Cancer Cells
Kowalski, S., Wyrzykowski, D., & Inkielewicz‐Stępniak, I. (2020) · Molecules · doi:10.3390/molecules25071757 · Cited by 88
Cisplatin Resistance: Genetic and Epigenetic Factors Involved
Lugones, Y., Loren, P., & Salazar, L. A. (2022) · Biomolecules · doi:10.3390/biom12101365 · Cited by 97
Cisplatin: an old drug with a newfound efficacy – from mechanisms of action to cytotoxicity
Macciò, A., & Madeddu, C. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.813934 · Cited by 86
Cisplatin electrochemical biosensor
Petrlová, J., Potěšil, D., Zehnálek, J., Sures, B., Adam, V., Trnková, L., & Kizek, R. (2006) · Electrochimica Acta · doi:10.1016/j.electacta.2006.03.077 · Cited by 86
Anti-tumor Efficiency of Lipid-coated Cisplatin Nanoparticles Co-loaded with MicroRNA-375
Tan, Y., Zhao, P., Rong, Z., Li, B., Xue, H., You, J., He, C., Li, W., He, X., Lee, R. J., et al. (2015) · Theranostics · doi:10.7150/thno.13130 · Cited by 81
Selective speciation improves efficacy and lowers toxicity of platinum anticancer and vanadium antidiabetic drugs
Doucette, K. K., Hassell, K. N., & Crans, D. C. (2016) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2016.09.013 · Cited by 80
Anti-cancer drugs interfere with intracellular calcium signaling
Florea, A.-M., & Büsselberg, D. (2009) · NeuroToxicology · doi:10.1016/j.neuro.2009.04.014 · Cited by 79
Cellular interactions of platinum drugs
Wexselblatt, E., Yavin, E., & Gibson, D. (2012) · Inorganica Chimica Acta · doi:10.1016/j.ica.2012.07.013 · Cited by 77
Cytoplasmic initiation of cisplatin cytotoxicity
Yu, F., Megyesi, J. K., & Price, P. M. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00593.2007 · Cited by 77
Nephroprotective Effects of Saponins from Leaves of Panax quinquefolius against Cisplatin-Induced Acute Kidney Injury
Ma, Z., Li, Y., Li, W., Yan, X., Yang, G., Zhang, J., Zhao, L., & Yang, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071407 · Cited by 74
Interactions of DNA with a New Platinum(IV) Azide Dipyridine Complex Activated by UVA and Visible Light: Relationship to Toxicity in Tumor Cells
Prachařová, J., Zerzánková, L., Štěpánková, J., Nováková, O., Farrer, N. J., Sadler, P. J., Brabec, V., & Kašpárková, J. (2012) · Chemical Research in Toxicology · doi:10.1021/tx300057y · Cited by 74
Magnetic nanoparticle hyperthermia enhancement of cisplatin chemotherapy cancer treatment
Petryk, A. A., Giustini, A. J., Gottesman, R. E., Kaufman, P. A., & Hoopes, P. J. (2013) · International Journal of Hyperthermia · doi:10.3109/02656736.2013.825014 · Cited by 72
Programmed cell death in trypanosomatids: a way to maximize their biological fitness?
Nguewa, P., Fuertes, M. A., Valladares, B., Alonso‐Moreno, C., & Pérez, J. M. (2004) · Trends in Parasitology · doi:10.1016/j.pt.2004.05.006 · Cited by 72
Self-citation
The relationship between platinum drug resistance and epithelial–mesenchymal transition
Brozović, A. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1912-7 · Cited by 72
Conformation of DNA GG Intrastrand Cross-Link of Antitumor Oxaliplatin and Its Enantiomeric Analog
Malina, J., Nováková, O., Vojtı́šková, M., Natile, G., & Brabec, V. (2007) · Biophysical Journal · doi:10.1529/biophysj.107.116996 · Cited by 70
Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer
Shord, S. S., Thompson, D. M., Krempl, G. A., & Hanigan, M. H. (2006) · Anti-Cancer Drugs · doi:10.1097/00001813-200602000-00013 · Cited by 69
Kinetic aspects of platinum anticancer agents
Ahmad, S. (2017) · Polyhedron · doi:10.1016/j.poly.2017.09.016 · Cited by 68
The Current and Future Therapies for Human Osteosarcoma
Lamplot, J. D., Denduluri, S. K., Qin, J., Li, R., Liu, X., Zhang, H., Chen, X., Wang, N., Pratt, A., Shui, W., et al. (2013) · Current Cancer Therapy Reviews · doi:10.2174/1573394711309010006 · Cited by 67
A Suggestion of Electrochemical Biosensor for Study of Platinum(II)‐DNA Interactions
Křížková, S., Adam, V., Petrlová, J., Zítka, O., Stejskal, K., Zehnálek, J., Sures, B., Trnková, L., Beklová, M., & Kizek, R. (2007) · Electroanalysis · doi:10.1002/elan.200603737 · Cited by 65
Effects of oxaliplatin on mouse myenteric neurons and colonic motility
Wafai, L., Taher, M., Jovanovska, V., Bornstein, J. C., Dass, C. R., & Nurgali, K. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00030 · Cited by 65
Antitumor and Cellular Pharmacological Properties of a Novel Platinum(IV) Complex:trans-[PtCl2(OH)2(Dimethylamine) (Isopropylamine)]
Perez, J. M. T., Kèlland, L. R., Montero, E. I., Boxall, F. E., Fuertes, M. A., Alonso‐Moreno, C., & Navarro‐Ranninger, C. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.4.933 · Cited by 64
Self-citation
Effect of Axial Coordination on the Electronic Structure and Biological Activity of Dirhodium(II,II) Complexes
Aguirre, J. D., Lutterman, D. A., Angeles-Boza, A. M., Dunbar, K. R., & Turró, C. (2007) · Inorganic Chemistry · doi:10.1021/ic700708g · Cited by 64
Structural and mechanistic aspects of platinum anticancer agents
Ahmad, S., Isab, A. A., & Ali, S. (2006) · Transition Metal Chemistry · doi:10.1007/s11243-006-0100-7 · Cited by 61
MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1
He, X., Xiao, X., Dong, L., Wan, N., Zhou, Z., Deng, H., & Zhang, X. (2014) · Tumor Biology · doi:10.1007/s13277-014-2814-z · Cited by 61
Is Autophagy Always a Barrier to Cisplatin Therapy?
Xu, J., & Gewirtz, D. A. (2022) · Biomolecules · doi:10.3390/biom12030463 · Cited by 60
Linear polyethyleneimine-based charge-reversal nanoparticles for nuclear-targeted drug delivery
Zhou, Z., Shen, Y., Tang, J., Jin, E., Ma, X., Sun, Q., Zhang, B., Kirk, E. A. V., & Murdoch, W. J. (2011) · Journal of Materials Chemistry · doi:10.1039/c1jm13576g · Cited by 59
PARP inhibition in platinum-based chemotherapy: Chemopotentiation and neuroprotection
McQuade, R. M., Stojanovska, V., Bornstein, J. C., & Nurgali, K. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.031 · Cited by 59
Immunohistochemical detection of platinated DNA in the cochlea of cisplatin-treated guinea pigs
van Ruijven, M. W. M., de Groot, J. C. M. J., Hendriksen, F. G. J., & Smoorenburg, G. F. (2005) · Hearing Research · doi:10.1016/j.heares.2004.12.007 · Cited by 58
WR-2721 (Amifostine) Ameliorates Cisplatin-Induced Hearing Loss But Causes Neurotoxicity In Hamsters: Dose-Dependent Effects
Church, M. W., Blakley, B. W., Burgio, D. L., & Gupta, A. K. (2004) · Journal of the Association for Research in Otolaryngology · doi:10.1007/s10162-004-4011-z · Cited by 57
Chemical inhibitor targeting the replication protein A–DNA interaction increases the efficacy of Pt-based chemotherapy in lung and ovarian cancer
Mishra, A. K., Dormi, S. S., Turchi, A. M., Woods, D. S., & Turchi, J. J. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.10.013 · Cited by 57
Co-inhibition of pol θ and HR genes efficiently synergize with cisplatin to suppress cisplatin-resistant lung cancer cells survival
Dai, C.-H., Chen, P., Li, J., Lan, T., Chen, Y., Qian, H., Chen, K., & Li, M. (2016) · Oncotarget · doi:10.18632/oncotarget.11214 · Cited by 61
Effect of Equatorial Ligands of Dirhodium(II,II) Complexes on the Efficiency and Mechanism of Transcription Inhibitionin Vitro
Chifotides, H. T., Fu, P. K. ‐., Dunbar, K. R., & Turró, C. (2004) · Inorganic Chemistry · doi:10.1021/ic034438m · Cited by 58
A Pyrazolato‐Bridged Dinuclear Platinum( II ) Complex Induces Only Minor Distortions upon DNA‐Binding
Télétchéa, S., Komeda, S., Teuben, J., Elizondo-Riojas, M.-Á., Reedijk, J., & Kozelka, J. (2006) · Chemistry - A European Journal · doi:10.1002/chem.200500923 · Cited by 56
Berberine, a Natural Product, Combined with Cisplatin Enhanced Apoptosis through a Mitochondria/Caspase-Mediated Pathway in HeLa Cells
Youn, M., So, H., Cho, H.-J., Kim, H.-J., Kim, Y., Lee, J., Sohn, J. S., Kim, Y. K., Chung, S.-Y., & Park, R. (2008) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.31.789 · Cited by 55
Personalized Medicine for Targeted and Platinum-Based Chemotherapy of Lung and Bladder Cancer
Cimino, G. D., Pan, C.-X., & Henderson, P. T. (2013) · Bioanalysis · doi:10.4155/bio.12.325 · Cited by 58
Hypoxia-induced cisplatin resistance is reversible and growth rate independent in lung cancer cells
Wohlkoenig, C., Leithner, K., Deutsch, A. J. A., Hrzenjak, A., Olschewski, A., & Olschewski, H. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.03.014 · Cited by 55
Predicting Ovarian Cancer Patients’ Clinical Response to Platinum-Based Chemotherapy by Their Tumor Proteomic Signatures
Yu, K., Levine, D. A., Zhang, H., Chan, D. W., Zhang, Z., & Snyder, M. P. (2016) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b01129 · Cited by 55
Cytotoxicity, cellular uptake, glutathione and DNA interactions of an antitumor large-ring PtII chelate complex incorporating the cis-1,4-diaminocyclohexane carrier ligand
Kašpárková, J., Suchánková, T., Halámiková, A., Zerzánková, L., Vrána, O., Margiotta, N., Natile, G., & Brabec, V. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.09.019 · Cited by 54
Hyaluronan-CD44 Promotes Phospholipase C–Mediated Ca2+ Signaling and Cisplatin Resistance in Head and Neck Cancer
Wang, S. J., & Bourguignon, L. (2006) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.132.1.19 · Cited by 54
Interleukin-6 modulates oxidative stress produced during the development of cisplatin nephrotoxicity
Mitazaki, S., Hashimoto, M., Matsuhashi, Y., Honma, S., Suto, M., Kato, N., Nakagawasai, O., Tan–No, K., Hiraiwa, K., Yoshida, M., et al. (2013) · Life Sciences · doi:10.1016/j.lfs.2013.01.026 · Cited by 53
Adenylate Kinase 3 Sensitizes Cells to Cigarette Smoke Condensate Vapor Induced Cisplatin Resistance
Chang, X., Ravi, R. K., Pham, V., Bedi, A., Chatterjee, A., & Sidransky, D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020806 · Cited by 52
Mitochondrial/lysosomal toxic cross-talk plays a key role in cisplatin nephrotoxicity
Pourahmad, J., Hosseini, M., Eskandari, M. R., Shekarabi, S. M., & Daraei, B. (2010) · Xenobiotica · doi:10.3109/00498254.2010.512093 · Cited by 52
Combination of cisplatin and bromelain exerts synergistic cytotoxic effects against breast cancer cell line MDA-MB-231 in vitro
Pauzi, A. Z. M., Yeap, S. K., Abu, N., Lim, K. L., Omar, A. R., Aziz, S. A., Chow, A. L. T., Subramani, T., Tan, S. G., & Alitheen, N. B. (2016) · Chinese Medicine · doi:10.1186/s13020-016-0118-5 · Cited by 54
Improvement of Cisplatin-induced renal dysfunction by Schisandra chinensis stems via anti-inflammation and anti-apoptosis effects
Li, Y., Ren, S., Yan, X., Li, H., Li, W., Zheng, B., Wang, Z., & Liu, Y. (2018) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2018.01.033 · Cited by 52
Synthesis and characterization of palladium(II) and platinum(II) complexes with Schiff bases derivatives of 2-pyridincarboxyaldehyde. Study of their interaction with DNA
García-Friaza, G., Fernández‐Botello, A., Perez, J. M. T., Prieto, M. J., & Moreno, V. (2006) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2006.03.011 · Cited by 52
Cisplatin up‐regulates ICAM‐1 expression in endothelial cell via a NF‐κB dependent pathway
Yu, M., Han, J., Cui, P., Dai, M., Li, H., Zhang, J., & Xiu, R. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00696.x · Cited by 51
An overview of recent advancements in anticancer Pt(IV) prodrugs: New smart drug combinations, activation and delivery strategies
Marotta, C., Giorgi, E., Binacchi, F., Cirri, D., Gabbiani, C., & Pratesi, A. (2023) · Inorganica Chimica Acta · doi:10.1016/j.ica.2023.121388 · Cited by 50
Effects of ginsenoside compound K combined with cisplatin on the proliferation, apoptosis and epithelial mesenchymal transition in MCF-7 cells of human breast cancer
Zhang, K., & Li, Y. (2015) · Pharmaceutical Biology · doi:10.3109/13880209.2015.1101142 · Cited by 49

Authors: Fuertes, M., Castilla, J., Alonso, C., & Pérez, J.
Affiliations: Universidad Autónoma de Madrid (ES)
Corresponding author: Castilla, J.
Pérez, J.
ORCID: Fuertes, M.
Alonso, C.
Venue: Current Medicinal Chemistry
Publisher: Bentham Science Publishers Ltd.
Published: 2003-02-01
Volume: 10
Issue: 3
Pages: 257-266
ISSN: 0929-8673 (ISSN-L)
DOI: 10.2174/0929867033368484
OpenAlex: W2146133266
Cited by: 432
References: 0
Citations by year: 2026: 3 · 2025: 14 · 2024: 31 · 2023: 38 · 2022: 21 · 2021: 14 · 2020: 17 · 2019: 13 · 2018: 15 · 2017: 21 · 2016: 22 · 2015: 15 · 2014: 30 · 2013: 28 · 2012: 27
FWCI: 5.98
Type: journal article
Language: en
Open access: closed
Locations: Current Medicinal Chemistry (publishedVersion)
PubMed (publishedVersion)
Funders: Fundación Ramón Areces
Topics: Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Keywords: cisplatin, mechanism of action, DNA adducts, phospholipid binding, phosphatidylserine, RNA binding, cytotoxicity, apoptosis, necrosis, cell death pathways, platinum-based chemotherapy
MeSH terms: Animals, Antineoplastic Agents, Binding Sites, Cisplatin, DNA Damage, DNA Repair, Humans, Necrosis, Neoplasms, Cell Death, Apoptosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cisplatin Biochemical Mechanism of Action: From Cytotoxicity to Induction of Cell Death Through Interconnections Between Apoptotic and Necrotic Pathways

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks